Sign In
Buy JAZZ
$252.86
-5.52 (-2.14%)
At Close: Jul 31, 2026
Cannabis-Derived Drug Maker GW Pharma Acquired by Jazz Pharma for $7.2 Billion
10:02am, Wednesday, 03'rd Feb 2021
Dublin-based Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) announced Wednesday morning that it has agreed to acquire London-based GW Pharmaceuticals PLC (NASDAQ: GWPH) for $220 per American depositary share
CBD Drug Makers, Medical Cannabis Stocks Rally On GW Pharma's Big Buyout
09:25am, Wednesday, 03'rd Feb 2021
Medical cannabis stocks and stocks of cannabinoid drug companies are rallying big time Wednesday, the catalyst being a multi-billion-dollar buyout in the space.
Jazz Pharmaceuticals buys GW Pharma for $7.2 billion
08:46am, Wednesday, 03'rd Feb 2021
Jazz Pharmaceuticals is buying GW Pharma for $7.2 billion in cash and stock, or $220 per share. CNBC's Becky Quick reports.
Jazz Pharmaceuticals to acquire GW Pharma for $7.2 billion in cash and stock
07:46am, Wednesday, 03'rd Feb 2021
Jazz Pharmaceuticals Plc said Wednesday it has agreed to acquire GW Pharmaceuticals Plc in a cash-and-stock deal valued at $7.2 billion. Under the terms of the deal, Jazz Pharma will pay $200 per shar
Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader
07:30am, Wednesday, 03'rd Feb 2021
DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement
7 Pharmaceutical Stocks With Exciting Plans for 2021
02:51pm, Wednesday, 13'th Jan 2021
Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.
Jazz (JAZZ) Initiates BLA Submission for Leukemia Candidate
11:17am, Tuesday, 22'nd Dec 2020
Jazz (JAZZ) initiates the submission of a BLA to the FDA for the marketing approval of JZP-458 for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma.
DUBLIN, Dec. 3, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ), along with its partner, PharmaMar (MSE: PHM), today announce results from the ATLANTIS Phase 3 multicenter, randomized, co
Jazz Pharmaceuticals Appoints Jennifer Cook and Mark Smith, M.D. to its Board of Directors
07:30am, Tuesday, 17'th Nov 2020
DUBLIN, Nov. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jennifer Cook and Mark D. Smith, M.D. have been appointed to the Company's Board of Directors, effect
Data at ASH 2020 Annual Meeting Highlights Jazz Pharmaceuticals' Commitment to Advancing Hematology/Oncology Research
07:30am, Thursday, 05'th Nov 2020
DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 11 company-sponsored abstracts, in addition to two abstracts from collaboration trials with The Univer
Jazz Pharmaceuticals plc's (JAZZ) CEO Bruce Cozadd on Q3 2020 Results - Earnings Call Transcript
10:34pm, Monday, 02'nd Nov 2020
Jazz Pharmaceuticals plc's (JAZZ) CEO Bruce Cozadd on Q3 2020 Results - Earnings Call Transcript
Jazz Pharmaceuticals: Q3 Earnings Insights
05:17pm, Monday, 02'nd Nov 2020
Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) moved higher by 7.9% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 5.12% year over year to $4
Jazz Pharmaceuticals's Earnings: A Preview
11:03am, Friday, 30'th Oct 2020
Jazz Pharmaceuticals (NASDAQ: JAZZ) releases its next round of earnings this Monday, November 02. Here is Benzinga's essential guide to Jazz Pharmaceuticals's Q3 earnings report.
BofA Securities Top 10 US Stock Ideas for the Rest of 2021
09:53am, Wednesday, 28'th Oct 2020
It is almost hard to believe, in what has been one of the most unbelievable years in recent history, that Halloween is this weekend and Thanksgiving is right around the corner.
Albireo's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
07:27am, Friday, 11'th Sep 2020
Albireo reports positive data from Phase 3 trial. Jazz Pharmaceuticals inks new cancer deal with Redx Pharma.
